SCHEMBL7536934

SCHEMBL7536934

O=C(NN=Cc1ccc(Cl)cc1)c1[nH]c2ccccc2c1C(=O)Nc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
LMNA P02545 4/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
THRB P10828 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
MEN1 O00255 7/20 0.56
KMT2A Q03164 7/20 0.56
MGAM O43451 1/20 0.53
GAA P10253 1/20 0.53
SI P14410 1/20 0.53
MGAM2 Q2M2H8 1/20 0.53
FAAH O00519 1/20 0.52
TUBB4A P04350 2/20 0.52
TUBB P07437 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7561385 1.00 MAPT (0.57) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL7564673 0.83 MAPT (0.64) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL7564668 0.83 MAPT (0.64) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL7530021 0.83 MAPT (0.59) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL7566498 0.83 MAPT (0.59) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL7530637 0.81 TUBB4A (0.70) MAPTSMN1; SMN2LMNARAB9ATHRB
SCHEMBL7673252 0.81 TUBB4A (0.70) MAPTSMN1; SMN2LMNARAB9ATHRB
SCHEMBL7561163 0.81 MAPT (0.61) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL7561164 0.81 MAPT (0.61) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL7672497 0.81 KMT2A (0.56) MAPTSMN1; SMN2LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885SMN1; SMN2 4745/4885LMNA 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.